290 related articles for article (PubMed ID: 34857011)
1. Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma.
Lanzi C; Favini E; Dal Bo L; Tortoreto M; Arrighetti N; Zaffaroni N; Cassinelli G
J Exp Clin Cancer Res; 2021 Dec; 40(1):381. PubMed ID: 34857011
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomas.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2022 Apr; 198():114944. PubMed ID: 35152144
[TBL] [Abstract][Full Text] [Related]
3. EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor.
Su L; Cheng H; Sampaio AV; Nielsen TO; Underhill TM
Oncogene; 2010 Jul; 29(30):4352-61. PubMed ID: 20514024
[TBL] [Abstract][Full Text] [Related]
4. Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.
Cassinelli G; Dal Bo L; Favini E; Cominetti D; Pozzi S; Tortoreto M; De Cesare M; Lecis D; Scanziani E; Minoli L; Naggi A; Vlodavsky I; Zaffaroni N; Lanzi C
Cancer Lett; 2018 Feb; 415():187-197. PubMed ID: 29225052
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
6. Death by HDAC Inhibition in Synovial Sarcoma Cells.
Laporte AN; Poulin NM; Barrott JJ; Wang XQ; Lorzadeh A; Vander Werff R; Jones KB; Underhill TM; Nielsen TO
Mol Cancer Ther; 2017 Dec; 16(12):2656-2667. PubMed ID: 28878027
[TBL] [Abstract][Full Text] [Related]
7. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
8. HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma.
Laporte AN; Barrott JJ; Yao RJ; Poulin NM; Brodin BA; Jones KB; Underhill TM; Nielsen TO
PLoS One; 2017; 12(1):e0169407. PubMed ID: 28056055
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
Zhou Q; Dalgard CL; Wynder C; Doughty ML
BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
[TBL] [Abstract][Full Text] [Related]
11. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
12. HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.
Lopez G; Song Y; Lam R; Ruder D; Creighton CJ; Bid HK; Bill KL; Bolshakov S; Zhang X; Lev D; Pollock RE
Mol Cancer Res; 2016 Jan; 14(1):35-43. PubMed ID: 26396249
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
14. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of the heparan sulfate mimic roneparstat (SST0001) against sarcoma models involves multi-target inhibition of receptor tyrosine kinases.
Cassinelli G; Favini E; Dal Bo L; Tortoreto M; De Maglie M; Dagrada G; Pilotti S; Zunino F; Zaffaroni N; Lanzi C
Oncotarget; 2016 Jul; 7(30):47848-47863. PubMed ID: 27374103
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.
Noack K; Mahendrarajah N; Hennig D; Schmidt L; Grebien F; Hildebrand D; Christmann M; Kaina B; Sellmer A; Mahboobi S; Kubatzky K; Heinzel T; Krämer OH
Arch Toxicol; 2017 May; 91(5):2191-2208. PubMed ID: 27807597
[TBL] [Abstract][Full Text] [Related]
17. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
18. ATR Is a Therapeutic Target in Synovial Sarcoma.
Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; van der Graaf WTA; Shipley J; Ashworth A; Lord CJ
Cancer Res; 2017 Dec; 77(24):7014-7026. PubMed ID: 29038346
[TBL] [Abstract][Full Text] [Related]
19. The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin.
Moyal L; Feldbaum N; Goldfeiz N; Rephaeli A; Nudelman A; Weitman M; Tarasenko N; Gorovitz B; Maron L; Yehezkel S; Amitay-Laish I; Lubin I; Hodak E
PLoS One; 2016; 11(1):e0146115. PubMed ID: 26752418
[TBL] [Abstract][Full Text] [Related]
20. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
